-

03:14:26 AM

DNLI Stock News

DNLI - Denali Therapeutics Inc

01/25/23 8:00 AM

Nasdaq : DNLI

clinical trial

Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi

Partner Sanofi has commenced dosing in a Phase 2 clinical trial of SAR443820 (DNL788) in individuals with multiple sclerosis Denali to receive a milestone payment of $25 million from Sanofi for Phase 2 clinical trial initiation Development of RIPK1 inhibitor program continues in a broad range of

RHEA-AI

neutral

01/09/23 8:00 AM

Nasdaq : DNLI

Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Four programs expected to progress in late-stage clinical studies for MPS II (Hunter syndrome), ALS, and Parkinson’s disease Further validation and expansion of Transport Vehicle (TV) technology, including multiple interim clinical data readouts, submission of IND for additional ETV program, and

RHEA-AI

neutral

12/05/22 7:00 AM

Nasdaq : DNLI

clinical trial

Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial

DNL343 demonstrated extensive blood-brain barrier penetration and robustly inhibited the integrated stress response pathway implicated in ALS Once-daily oral dosing with DNL343 for 28 days was generally well tolerated in participants with ALS The design phase for entry of DNL343 into a Phase 2/3

RHEA-AI

neutral

11/03/22 4:01 PM

Nasdaq : DNLI

earnings

Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results

RHEA-AI

neutral

11/01/22 8:00 AM

Nasdaq : DNLI

clinical trial

Denali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with TAK-594/DNL593 (PTV:PGRN) and Progression to Enrolling Participants with FTD-GRN

Interim results from Part A in healthy volunteers demonstrated dose-dependent increases in CSF progranulin levels, consistent with robust brain delivery of DNL593 Single doses of DNL593 were generally well tolerated Data support progression to enrolling participants with FTD-GRN in Part B of the

RHEA-AI

negative

10/24/22 4:30 PM

Nasdaq : DNLI

offering

Denali Therapeutics Announces Closing of a $316 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the closing of its upsized underwritten public offering of 11,933,962 shares of its common stock at a price to the public of $26.50 per share, which includes the exercise in full

RHEA-AI

neutral

10/19/22 9:19 PM

Nasdaq : DNLI

offering

Denali Therapeutics Announces Pricing of $275 Million Public Offering of Common Stock

Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 10,377,359 shares of its common stock at a price to the public of $26.50 per share. All of the shares are to be sold by Denali

RHEA-AI

neutral

10/18/22 4:40 PM

Nasdaq : DNLI

offering

Denali Therapeutics Announces Proposed Offering of Common Stock

Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell $250 million of shares of its common stock in an underwritten public offering. In addition, Denali Therapeutics intends to grant the

RHEA-AI

neutral

10/03/22 8:00 AM

Nasdaq : DNLI

clinical trial

Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations

Global Phase 3 study to evaluate efficacy and safety of BIIB122, a small molecule inhibitor of LRRK2 LRRK2 mutations are one of the most common genetic drivers of Parkinson’s disease Targeting LRRK2 has the potential to impact the underlying biology and slow the progression of Parkinson’s disease

RHEA-AI

neutral

08/31/22 8:00 AM

Nasdaq : DNLI

clinical trial

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2022

Additional one-year data continue to show rapid and sustained normalization to healthy levels of CSF heparan sulfate and improvements in biomarkers of lysosomal function consistent with durable central nervous system activity Safety profile, now with up to 85 weeks of dosing, continues to be

RHEA-AI

neutral

1 2 3 4 5 6 Next

DNLI Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.denalitherapeutics.com
CeoRyan Watts
Security nameDenali Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2836
Employees291
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Address161 Oyster Point Blvd
StateCalifornia
CitySouth San Francisco
Zip94080-1910
CountryUS
Phone16508668548

About Denali Therapeutics Inc

Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco.